The European Commission’s CORDIS coverage of how Horizon is powering the EU biotechnology industry points to an important shift: biotechnology is no longer treated only as a research-intensive scientific field. It is increasingly being positioned as economic infrastructure for Europe’s health, food, industrial production, climate targets and strategic resilience.
For readers looking for a European alternative to dependency on non-European technology platforms, pharmaceutical supply chains and industrial inputs, this matters. Biotechnology can replace or improve processes currently reliant on fossil feedstocks, imported active ingredients, resource-heavy agriculture or intellectual property controlled outside Europe. But public research funding alone will not create that alternative. Europe must be able to turn laboratory results into regulated products, manufacturing capacity and sustainable businesses.
Horizon support can help address the earliest and riskiest stages of that journey. Its real significance is not just the grant amount awarded to individual projects; it is the ability to build cross-border research consortia, validate technical approaches, establish data and standards, and make emerging fields investable.
Why biotechnology has become a European competitiveness issue
Biotechnology applies living cells, biological systems and biological data to create products or processes. Its practical uses are already broad: vaccines and diagnostics, precision fermentation, alternative proteins, bio-based materials, enzyme-based manufacturing, crop resilience, wastewater treatment and new methods for producing chemicals.
From scientific excellence to industrial capacity
Europe has leading universities, clinical research centres, specialist small and medium-sized enterprises, and a substantial life-sciences base. Yet a persistent European challenge is commercial scale-up. A company can demonstrate a promising molecule, microbial strain, platform or medical device in a research setting, but still struggle to finance pilot plants, clinical development, quality systems, regulatory work and first commercial production.
This gap is especially acute in biotech because timelines are long and risks are layered. A technology must work scientifically, be reproducible at scale, meet safety and quality requirements, obtain regulatory approval where applicable, compete on cost, and secure buyers. Traditional investors often hesitate before these questions are answered, while banks generally do not finance high-risk pre-revenue development.
Horizon-funded projects can reduce some of that uncertainty. Collaborative grants can produce independent validation, shared demonstrators, early evidence of performance, and networks that include universities, hospitals, manufacturers and end users. Those assets may make a company or technology more credible to later-stage investors.
However, grant funding should not be confused with a complete route to market. The key test is whether Horizon-supported innovation can attract follow-on capital and find European sites capable of manufacturing at commercial scale.
Strategic autonomy does not mean isolation
A stronger EU biotech sector is often discussed through the lens of strategic autonomy. In practical terms, this means retaining the capacity to research, develop, produce and procure technologies that are essential to European public interests. It does not require Europe to cut itself off from global scientific collaboration or trade.
Instead, it means reducing dangerous concentrations of dependency. If Europe depends heavily on a small number of overseas suppliers for critical medicines, biological raw materials, specialised equipment, cloud-based biological data processing or food-system inputs, disruption can rapidly become a public-health or economic problem. The COVID-19 pandemic demonstrated the value of domestic and regional research, manufacturing and procurement capability, even within highly globalised supply chains.
Biotechnology is therefore relevant to resilience, but only if Europe builds capacity beyond publications and patents. Manufacturing know-how, skilled operators, bioprocess engineering, quality assurance and dependable supply chains deserve the same attention as scientific discovery.
What this means for European biotech businesses
For founders, researchers and established manufacturers, the CORDIS focus is a signal that EU-level biotechnology policy is tied increasingly to investment and deployment. That creates opportunity, but it also raises expectations.
A Horizon project should answer a market question
Applicants should avoid treating Horizon as funding for a technology in isolation. A stronger proposal explains the specific bottleneck it solves and who will adopt it. For example:
- A health biotech venture should define the unmet clinical need, the evidence pathway, likely regulatory route and reimbursement context.
- An industrial biotech company should quantify feedstock needs, energy use, expected yield, production economics and potential offtake customers.
- An agrifood biotech project should account for consumer acceptance, farmer incentives, traceability and the legal status of its product across relevant EU markets.
The most persuasive projects connect technical progress with a credible route to deployment. That includes a plan for intellectual-property management, data governance, scale-up partners and post-grant finance.
Partnerships are a commercial asset, not merely an eligibility requirement
Cross-border consortia can be administratively demanding, but they offer a major advantage when designed well. A university may contribute foundational science, a small company may supply a proprietary platform, a hospital may provide clinical validation, and an industrial partner may assess manufacturing feasibility.
Businesses should choose partners based on what they can do after the grant ends. A pilot facility, contract development and manufacturing organisation, clinical site, prospective customer or regional cluster can be more valuable than a large consortium member with no defined operational role.
Build the investment story early
Public grants may fund research and demonstration, but private or blended finance is usually needed for scale-up. Companies should begin investor preparation before the end of a project. This means maintaining clear data rooms, documenting freedom to operate, recording reproducibility results, and setting measurable milestones that investors can understand.
A useful question for management teams is: what evidence will this project generate that reduces the next investor’s risk? If the answer is vague, the work plan may be scientifically interesting but commercially incomplete.
What consumers and citizens should watch
For citizens, the value of public biotech funding should be assessed through outcomes rather than announcements. Does a project contribute to more reliable medicine supply? Does it lower the environmental footprint of a material without shifting impacts elsewhere? Does it create skilled employment and manufacturing capacity in Europe? Are safety, ethics and public transparency built into the development process?
Biotechnology should not be framed as automatically sustainable simply because it uses biology. A fermentation process may require substantial energy; a bio-based input may create new land-use pressures; and the collection of genomic or health data can raise serious privacy concerns. Public support should therefore be paired with lifecycle assessment, robust safety evaluation, transparent communication and compliance with EU data-protection rules.
This scrutiny is not anti-innovation. It is how Europe can make biotech innovation trustworthy enough to earn public acceptance and durable market demand.
The policy challenge: connecting research, regulation and scale
Europe’s opportunity is considerable, but its policy challenge is equally clear. It must ensure that research programmes, regulatory systems, industrial policy and investment instruments reinforce one another.
A startup cannot benefit fully from a successful research project if approval pathways are unclear, pilot infrastructure is unavailable, or scale-up capital moves abroad. Likewise, industrial investment will remain cautious if scientific evidence is weak or regulatory requirements are applied inconsistently between Member States.
Policymakers should therefore focus on practical bridges: access to pilot and demonstration facilities; clearer and proportionate regulatory guidance; public procurement that rewards validated European solutions where lawful; stronger links between Horizon projects and later-stage financing; and training for biomanufacturing roles.
For the European alternative agenda, the objective is not to subsidise every promising laboratory idea indefinitely. It is to build an ecosystem in which European discoveries can become responsibly governed, commercially viable technologies made and used in Europe.
Practical next steps
For biotech SMEs and researchers
- Map the technology’s route from proof of concept to market, including regulatory, manufacturing and financing milestones.
- Identify consortium partners that can validate real-world use and support scale-up.
- Define measurable commercial outcomes alongside scientific objectives.
- Prepare intellectual-property and data-governance plans before entering collaborations.
- Track Horizon calls and complementary national or regional funding, but plan for post-grant investment from the outset.
For investors and industrial buyers
- Look beyond patent portfolios and assess manufacturability, regulatory readiness and supply-chain exposure.
- Engage early with Horizon-backed projects to shape pilots, offtake agreements or validation studies.
- Consider whether European production capacity offers resilience value that is not visible in a simple unit-cost comparison.
FAQ
Does Horizon funding guarantee that a biotech product will reach the market?
No. Horizon funding can de-risk research, validation and collaboration, but commercial launch still depends on regulatory approval, manufacturing, capital, customer demand and competitive economics.
Why is biotech relevant to European strategic autonomy?
Biotech can support more resilient access to medicines, diagnostics, industrial materials, food-related inputs and production technologies. The strategic benefit comes from retaining European capability across research, data, manufacturing and procurement.
What should a biotech startup do after receiving a Horizon grant?
It should use the project to generate evidence that helps secure the next stage of finance: reproducible data, pilot results, regulatory engagement, intellectual-property clarity, manufacturing partners and prospective customers.
Can biotech solutions be sustainable by default?
No. Their environmental and social impact depends on energy use, feedstocks, land use, waste, supply chains and data practices. Lifecycle assessment and transparent oversight are essential.
Source: CORDIS | European Commission — Tue, 22 Sep 2026 21:28:33 GMT
